Compare ETS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | CMMB |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Israel |
| Employees | 26 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.2M |
| IPO Year | N/A | 2023 |
| Metric | ETS | CMMB |
|---|---|---|
| Price | $0.64 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 25.6K | ★ 36.0K |
| Earning Date | 04-13-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $37.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.87 |
| 52 Week High | $1.21 | $3.86 |
| Indicator | ETS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 38.28 |
| Support Level | $0.49 | $1.41 |
| Resistance Level | $0.67 | $1.64 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 51.16 | 14.06 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.